Apotex Inc. v. Sanofi-Aventis, 2014 FCA 68 (Ramipril*)
Justice Sharlow; Justice Pelletier; Justice Mainville - 2014-03-14
Read full decision. Automatically generated summary:
The decision primarily relates to an appeal brought by Apotex from a judgment of Snider J. cited as 2012 FC 553, which ordered compensation to be paid to pursuant to section 8 of the Patented Medicines (Notice of Compliance) Regulations for its net lost profits in respect of 1.25, 2.5, 5 and 10 mg capsules of its generic version of the drug ramipril for the period commencing April 26, 2004 and ending December 12, 2006 and subsequent appeal brought by Sanofi from a subsequent judgment of the Trial Judge dated which ordered, further to the Liability Judgment, the precise amount to be paid by Sanofi to Apotex, together with post-judgment interest.
Decision relates to:
- A-191-12 - APOTEX INC. v. SANOFI-AVENTIS ET AL which is an appeal from 2012 FC 553 in T-1357-09
- A-193-12 - SANOFI-AVENTIS ET AL v. APOTEX which is an appeal from 2012 FC 552 in T-1161-07
- A-397-12 - SANOFI AVENTIS ET AL v. APOTEX INC. which is an appeal from a decision dated 2012-06-22 in T-1357-09
- A-474-12 - SANOFI-AVENTIS ET AL v. APOTEX INC. which is an appeal from a decision dated 2012-11-02 in T-1357-09
- A-479-12 - ANIMALERIE DYNO INC c. AGENCE DU REVENU DU CANADA